Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion
, 2020 Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena +4 more
core +1 more source
Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis : mission possible? [PDF]
, 2017 A
Ceelen, Wim +5 more
core +2 more sources
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]
, 2015 Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim +6 more
core +4 more sources
Peritoneal carcinomatosis [PDF]
, 2013 Several gastrointestinal and gynecological malignancies have the potential to disseminate and grow in the peritoneal cavity. The occurrence of peritoneal carcinomatosis (PC) has been shown to significantly decrease overall survival in patients with liver
Ansaloni L +10 more
core +1 more source
Intraperitoneal hyperthermic chemotherapy in ovarian cancer
International Journal of Gynecological Cancer, 2005 We investigated the effect of intraperitoneal hyperthermic perfusion chemotherapy as consolidation therapy in stage IIIB-IIIC ovarian cancer, following cytoreductive surgery and systemic chemotherapy (cisplatin-cyclophosphamide--six cycles). Disease-free survival, overall survival, and side effects were compared with a control group of patients who ...
M. Toziano +6 more
openaire +3 more sources
Role of hyperthermic intraperitoneal chemotherapy in ovarian cancer [PDF]
Chinese Clinical Oncology, 2020 Epithelial ovarian cancer (EOC), has the highest worldwide mortality of all gynecological tumors, in 75% of cases is diagnosed in advanced stages. Despite of treatments with maximal cytoreductive surgery (CRS) and platinum-based chemotherapy (CT), approximately 70% of patients with advancedstage disease relapse within 18 months, given this high number ...
Adriana Ruiz-DeLeón +1 more
openaire +2 more sources
Pleura and Peritoneum, 2022 Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is associated with increased morbidity and mortality. We retrospectively analysed the perioperative anesthetic management in patients undergoing HIPEC surgery.
Gupta Raghav +15 more
doaj +1 more source
Intraperitoneal chemotherapy for gastric cancer with peritoneal carcinomatosis: is HIPEC the only answer? [PDF]
, 2014 Gastric cancer with peritoneal carcinomatosis is notorious for its dismal prognosis. While the pathophysiology of peritoneal dissemination is still controversial, the rapid downhill course is universal.
Kwong, DLW, Lam, KO, Law, BTT, Law, SYK
core +1 more source
Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer [PDF]
, 2019 Patients with advanced ovarian cancer develop recurrence despite initial treatment response to standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a limited peritoneal exposure time of chemotherapeutics ...
Ceelen, Wim +7 more
core +2 more sources
Single Center Experience With Hyperthermic Intraperitoneal Chemotherapy [PDF]
Annals of Coloproctology, 2017 Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been proposed for controlling peritoneal seeding metastasis in some kinds of cancers, including those of colorectal origin, but their safety and oncological benefits are subjects of debate.
Byung Soh Min +5 more
openaire +4 more sources